Update on funding for pazopanib and regorafenib in the NHS

Pazopanib (Votrient)

The BSG has been informed that pazopanib (Votrient from GSK) for advanced soft tissue sarcoma will not be referred to NICE by the Department of Health. This is understood to be because the numbers of patients are too small to justify the use of the NICE Single Technology Appraisal process, and that the price of the drug is now determined by its approval for use in RCC.

The new National Cancer Drugs Fund approved list allows funding of the drug for use in the NHS in England.

The SMC appraisal has refused funding for the NHS in Scotland. The All Wales Medicines Strategy Group review of the treatment has also refused approval. In both cases the cost effectiveness case was regarded as not proven.

Regorafenib (Stivarga)

The BSG has been informed that regorafenib (Stivarga from Bayer) for use in third-line with GIST will not be referred to NICE by the Department of Health, assuming it is given marketing authorisation by EMA. The drug is licensed for colo-rectal cancer and is available off-label.

 

It has been added to the National Cancer Drugs Fund approved list . This allows funding of the drug for use in the NHS in England.

 

Decisions from SMC for the NHS in Scotland and AWMSG for Wales will not be taken until EMA has authorised the indication.

This entry was posted in
Go to news